MAT-XU-2305030 (v2.0)
Date of Preparation: February 2025
Website is intended for United Kingdom patients who have been prescribed REZUROCK
Website is intended for United Kingdom patients who have been prescribed REZUROCK
REZUROCK is used to treat adults and adolescents aged 12 years and older with chronic graft-versus-host disease who have
received at least two previous treatments.
REZUROCK is used to treat adults and adolescents aged 12 years and older with chronic graft-versus-host disease who have
received at least two previous treatments.
MAT-XU-2305030 (v2.0)
Date of Preparation: February 2025
YOU ARE LEAVING THE REZUROCK UK WEBSITE
This link will take you to a website to which our Privacy Policy does not apply. Sanofi UK has no control over the contents of these sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them.
Click the "Continue" button below to go to the page you requested or click "Cancel" to remain on this page.
This website and its contents have been developed for patients in the United Kingdom who have been prescribed REZUROCK.
In order to proceed into the website, please confirm that you are, or you care for, a patient in the United Kingdom prescribed REZUROCK by clicking the confirmation button below.
This website is not intended for children under 12 years of age. If you are under 12 years old, please make sure your parents or legal guardian agrees for you to visit the website.
MAT-XU-2303463 (v2.0) Date of Preparation: February 2025
REZUROCK▼ PATIENTS
This website and its contents have been developed for patients in the United Kingdom who have been prescribed REZUROCK (belumosudil).
In order to proceed into the website, please confirm that you are, or you care for, a patient in the United Kingdom prescribed REZUROCK by clicking the confirmation button below.
This website is not intended for children under 12 years of age. If you are under 12 years old, please make sure your parents or legal tutor agrees for you to visit this website.
MAT-XU-2303463 (v2.0) Date of Preparation: February 2025